Faes Farma SA
MAD:FAE
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.935
3.805
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Faes Farma SA
Net Income (Common)
Faes Farma SA
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
Faes Farma SA
MAD:FAE
|
Net Income (Common)
€97.6m
|
CAGR 3-Years
7%
|
CAGR 5-Years
1%
|
CAGR 10-Years
15%
|
|
|
Almirall SA
MAD:ALM
|
Net Income (Common)
-€35.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-11%
|
|
|
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
|
Net Income (Common)
€217.2m
|
CAGR 3-Years
12%
|
CAGR 5-Years
35%
|
CAGR 10-Years
25%
|
|
|
Laboratorio Reig Jofre SA
MAD:RJF
|
Net Income (Common)
€11.7m
|
CAGR 3-Years
29%
|
CAGR 5-Years
1%
|
CAGR 10-Years
25%
|
|
Faes Farma SA
Glance View
Faes Farma SA, a notable player in the pharmaceutical arena, has orchestrated its operations with the precision of a seasoned conductor. Rooted in Spain with an impressive international reach, the company blends research prowess with adept production capabilities. Central to its modus operandi is the development, manufacture, and commercialization of a wide range of pharmaceutical products and nutritional supplements. With science as its guiding star, Faes Farma dedicates substantial resources to research and development, ensuring a pipeline filled with innovative treatments that cater to diverse medical needs. The company has carved its niche by focusing on therapeutic areas such as allergy, dermatology, and the central nervous system, allowing it to create specialized solutions that resonate well with healthcare providers and patients alike. The company’s revenue engine is driven primarily by its robust product sales, enhanced by strategic partnerships and licensing agreements that bolster its market presence both in Spain and across global markets. Through rigorous production processes, Faes Farma ensures the delivery of high-quality medications, matching industry standards and fostering consumer trust. Additionally, its geographical diversification, with subsidiaries and distribution channels spreading across Europe, Latin America, and Africa, underpins its economic durability. By marrying innovation with strategic commercial tactics, Faes Farma has deftly navigated the complexities of the pharmaceutical landscape, ensuring not only profitability but also the sustained delivery of health-enhancing products to the global community.
See Also
What is Faes Farma SA's Net Income (Common)?
Net Income (Common)
97.6m
EUR
Based on the financial report for Sep 30, 2024, Faes Farma SA's Net Income (Common) amounts to 97.6m EUR.
What is Faes Farma SA's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
15%
Over the last year, the Net Income (Common) growth was 9%. The average annual Net Income (Common) growth rates for Faes Farma SA have been 7% over the past three years , 1% over the past five years , and 15% over the past ten years .
You don't have any saved screeners yet
